Business
New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKD
New analysis from landmark Phase 3 PRECISION trial published in Hypertension highlights the renal-protective benefits of aprocitentan in addition to the marked reduction in blood pressure in a high-risk CKD population with difficult-to-control hypertension Allschwil, Switzerland – December 10, 2025Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in Hypertension titled “Aprocitentan in Patients with Chronic Kidney Disease and Resistant
About this update from Idorsia Ltd.
[{"type":"image","alt":"Idorsia Pharmaceuticals Ltd","displaySize":"","headline":null,"caption":"Idorsia Pharmaceuticals Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/atcBYtwjtI326vFfueDYtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a","width":300,"height":138}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"New analysis from landmark Phase 3 PRECISION trial published in Hypertension highlights the renal-protective benefits of aprocitentan in addition to the marked reduction in blood pressure in a high-risk CKD population with difficult-to-control hypertension","length":256,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":256,"olType":false},{"type":"text","content":"Allschwil, Switzerland – December 10, 2025Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in Hypertension titled “Aprocitentan in Patients with Chronic Kidney Disease and Resistant Hypertension”.1 The analysis examined the efficacy and safety of aprocitentan (TRYVIO™/JERAYGO™) in patients with chronic kidney disease (CKD) and confirmed resistant hypertension – a population with very limited treatment options and high cardiovascular and renal risk.","length":514,"tagName":"p"},{"type":"text","content":"Aprocitentan, the first approved antihypertensive targeting the endothelin pathway, was well tolerated. It significantly reduced both office and nighttime ambulatory blood pressure (BP), as well as markedly lowered albuminuria – a key marker of kidney damage – without increasing the risk of hyperkalemia.","length":305,"tagName":"p"},{"type":"text","content":"Patrick Rossignol, MD, PhD, nephrologist, Head of the Medical Specialties and nephrology departments at the Princess Grace Hospital, Monaco, commented:“Hypertension is both a cause and consequence of chronic kidney disease (CKD) and managing it in these patients is particularly challenging. Blood pressure is often difficult to control, and many antihypertensive agents carry risks of worsening renal function or causing hypo or hyperkalemia, which are all associated with dismal ou...